Sol-Gel Technologies (STU:4SG) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4SG Sol-Gel Technologies Ltd STU:4SG
45 GF Score
Price €66.50
GF Value €5.12
! 2 Warning Signs
View Full Analysis

What is Sol-Gel Technologies FFO per Share?

FFO per Share only applies to REITs.

STU:4SG
45GF Score
Sol-Gel Technologies Ltd STU:4SG
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sol-Gel Technologies (STU:4SG) Overvalued in 2026?

Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued. The current stock price of €66.50 is trading 1198.8% above its estimated GF Value™ of €5.12.

Key valuation signals for STU:4SG:

  • FFO per Share:
  • GF Value™: €5.12 vs. price of €66.50 (1198.8% above fair value)
  • GF Score™: 45/100 with 2 warning signs

No single metric tells the full story. See the STU:4SG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sol-Gel Technologies Business Description

Other Exchanges SLGL:USA4SG:Germany
Address 7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
45GF Score

Get the complete analysis for STU:4SG

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.50
Price
€5.12
GF Value